Trending...
- IDEMIA Awarded 10-Year Blanket Purchase Agreement from the General Services Administration for Next-Generation Identity Proofing for Login.Gov - 315
- Sarah Novotny Joins Kosai as a Board Advisor: A New Chapter for Open Source Leadership
- NY Implant Dentistry - Dr. Greg R. Diamond, DDS – Your Trusted Dentist in NYC, New York
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Sangamo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3.
More on Nyenta.com
In a press release announcing this development, Sangamo stated that it was "surprised and extremely disappointed by Pfizer's decision" to end the collaboration so close to anticipated Biologics License Application and Marketing Authorisation Application submissions for giroctocogene fitelparvovec, which the Company had expected to occur in early 2025.
The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec program back to Sangamo.
On this news, Sangamo's stock price fell sharply during intraday trading on December 31, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
More on Nyenta.com
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Sangamo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3.
More on Nyenta.com
- Exciting News: Gourmet Meal Kiosks Coming to Wilmorite Malls in Rochester, NY!
- Holistic Energy Bodyworks Launches New Website to Transform Wellness
- Yonkers: HOLLYWOOD ON HUDSON: YONKERS FILM AND TELEVISION PRODUCTION SOARS IN 2024
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- TilePix x Jonathan Adler Introduce The Jet Set Collection
In a press release announcing this development, Sangamo stated that it was "surprised and extremely disappointed by Pfizer's decision" to end the collaboration so close to anticipated Biologics License Application and Marketing Authorisation Application submissions for giroctocogene fitelparvovec, which the Company had expected to occur in early 2025.
The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec program back to Sangamo.
On this news, Sangamo's stock price fell sharply during intraday trading on December 31, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
More on Nyenta.com
- New-and-Improved Caribbean-Food Website Dishes Out Free Ground-Shipping Offer; Affiliate Program Garnished with Generous Commission
- 50th Mount Dora Arts Festival set for Feb 1 and 2, 2024
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
- LINE FRIENDS and HoYoverse to Debut Genshin minini POP-UP at LINE FRIENDS Flagship Store in New York City's Times Square Starting January 22nd
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- LIB: A master of ingenuity in the field of custom test chambers, unlocking unlimited possibilities!
- Anatomage Announces Acquisition of Cloud-based Software Company BioDigital
- PRP Aviation Earns Prestigious "Platinum Cirrus Training Center" Designation
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - SDIG, IPXX, KAVL, ML
- New Rochelle Job Fair at City Hall, Wednesday, January 22
- Richard Contino's 'Equipment Leasing and Financing' A Manufacturer's Guide to Captive Financing
- MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference
- Growth Marshal Publishes Comprehensive Guide to Content Marketing for CEOs
- Cyrus Webb and Conversations Media Group Providing New Opportunities for Authors and Creatives to Shine and Thrive
- Tam Tam Named Best Children's Music Education & Wellness Organization in New York
- Westchester Network for Professionals Launches Exclusive New Year Membership Offer
- Seeking Sponsors for the BizNetwork Destination Tours Launch Party & Networking Social Gala
- Inframark Acquires Cornerstone Properties, Inc., Expanding Community Management Services in Arizona
- Loose, Uncomfortable Dentures? Get a Same-Day Reline While-U-Wait!
- IDEMIA Awarded 10-Year Blanket Purchase Agreement from the General Services Administration for Next-Generation Identity Proofing for Login.Gov
- New Report Highlights Opportunities and Barriers in Finger Lakes Clean Energy Workforce
- Rochester: Statement by Mayor Evans regarding life of President Jimmy Carter on National Day of Mourning
- NY Implant Dentistry - Dr. Greg R. Diamond, DDS – Your Trusted Dentist in NYC, New York
- ITURAN ANNOUNCES PARTICIPATION IN UPCOMING CONFERENCES IN JANUARY 2025
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against BioAge Labs, Inc. - BIOA